Predictive Risk Factors for Early Recurrence of Stage pIIIA-N2 Non-Small Cell Lung Cancer

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30. doi:10.3322/caac.2159031912902
   PubMed Web of Science ®Google Scholar
• Molina JR, Yang P, Cassivi SD, Schild SE, Adjei AA. Non-small cell lung cancer: epidemiology, risk factors, treatment, and survivorship. Mayo Clin Proc. 2008;83(5):584–594. doi:10.1016/S0025-6196(11)60735-018452692
   PubMed Web of Science ®Google Scholar
• Gillaspie EA, Wigle DA. Management of stage IIIA (N2) non-small cell lung cancer. Thorac Surg Clin. 2016;26(3):271–285. doi:10.1016/j.thorsurg.2016.04.00127427522
   PubMed Web of Science ®Google Scholar
• Darling GE, Li F, Patsios D, et al. Neoadjuvant chemoradiation and surgery improves survival outcomes compared with definitive chemoradiation in the treatment of stage IIIA N2 non-small-cell lung cancer. Eur J Cardiothorac Surg. 2015;48(5):684–690; discussion 690. doi:10.1093/ejcts/ezu504
   Web of Science ®Google Scholar
• Kim DW, Yun JS, Song SY, Na KJ. The prognosis according to patterns of mediastinal lymph node metastasis in pathologic stage IIIA/N2 non-small cell lung cancer. Korean J Thorac Cardiovasc Surg. 2014;47(1):13–19. doi:10.5090/kjtcs.2014.47.1.1324570860
   PubMedGoogle Scholar
• Silvestri GA, Gonzalez AV, Jantz MA, et al. Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3rd ed: American College of Chest Physicians evidence-based clinical practice guidelines. Chest. 2013;143(5Suppl):e211S–e250S. doi:10.1378/chest.12-235523649440
   PubMed Web of Science ®Google Scholar
• Massard G, Renaud S, Reeb J, Santelmo N, Olland A, Falcoz PE. N2-IIIA non-small cell lung cancer: a plea for surgery! J Thorac Dis. 2016;8(Suppl 11):S849–S854. doi:10.21037/jtd.2016.09.3427942406
   PubMed Web of Science ®Google Scholar
• Feng W, Fu XL, Cai XW, et al. Patterns of local-regional failure in completely resected stage IIIA(N2) non-small cell lung cancer cases: implications for postoperative radiation therapy clinical target volume design. Int J Radiat Oncol Biol Phys. 2014;88(5):1100–1107. doi:10.1016/j.ijrobp.2013.12.04824529715
   PubMed Web of Science ®Google Scholar
• Iwasaki A, Shirakusa T, Miyoshi T, et al. Prognostic significance of subcarinal station in non-small cell lung cancer with T1-3 N2 disease. Thorac Cardiovasc Surg. 2006;54(1):42–46. doi:10.1055/s-2005-86582816485188
   PubMed Web of Science ®Google Scholar
• Dai H, Hui Z, Ji W, et al. Postoperative radiotherapy for resected pathological stage IIIA-N2 non-small cell lung cancer: a retrospective study of 221 cases from a single institution. Oncologist. 2011;16(5):641–650. doi:10.1634/theoncologist.2010-034321482587
   PubMed Web of Science ®Google Scholar
• Yoo C, Yoon S, Lee DH, et al. Prognostic significance of the number of metastatic pN2 lymph nodes in stage IIIA-N2 non-small-cell lung cancer after curative resection. Clin Lung Cancer. 2015;16(6):e203–212. doi:10.1016/j.cllc.2015.04.00425997733
   PubMed Web of Science ®Google Scholar
• Nakagiri T, Sawabata N, Funaki S, et al. Validation of pN2 sub-classifications in patients with pathological stage IIIA N2 non-small cell lung cancer. Interact Cardiovasc Thorac Surg. 2011;12(5):733–738. doi:10.1510/icvts.2010.24989621297135
   PubMed Web of Science ®Google Scholar
• Ichinose Y, Kato H, Koike T, et al. Overall survival and local recurrence of 406 completely resected stage IIIa-N2 non-small cell lung cancer patients: questionnaire survey of the Japan Clinical Oncology Group to plan for clinical trials. Lung Cancer. 2001;34(1):29–36. doi:10.1016/S0169-5002(01)00207-011557110
   PubMed Web of Science ®Google Scholar
• Inoue M, Sawabata N, Takeda S, Ohta M, Ohno Y, Maeda H. Results of surgical intervention for p-stage IIIA (N2) non-small cell lung cancer: acceptable prognosis predicted by complete resection in patients with single N2 disease with primary tumor in the upper lobe. J Thorac Cardiovasc Surg. 2004;127(4):1100–1106. doi:10.1016/j.jtcvs.2003.09.01215052208
   PubMed Web of Science ®Google Scholar
• Wei W, Zhou J, Zhang Q, et al. Postoperative intensity-modulated radiation therapy reduces local recurrence and improves overall survival in III-N2 non-small-cell lung cancer: a single-center, retrospective study. Cancer Med. 2020;9(8):2820–2832. doi:10.1002/cam4.293732100444
   PubMed Web of Science ®Google Scholar
• Feng W, Zhang Q, Fu XL, et al. The emerging outcome of postoperative radiotherapy for stage IIIA(N2) non-small cell lung cancer patients: based on the three-dimensional conformal radiotherapy technique and institutional standard clinical target volume. BMC Cancer. 2015;15:348. doi:10.1186/s12885-015-1326-625934006
   PubMed Web of Science ®Google Scholar
• Noel G, Mazeron JJ, Wagner H. [A randomized trial of postoperative adjuvant therapy in patients with completely resected stage II or IIIa non-small-cell lung cancer]. Cancer Radiother. 2001;5(2):195–196. Dutch. doi:10.1016/S1278-3218(00)00066-411355584
   PubMedGoogle Scholar
• Sawyer TE, Bonner JA, Gould PM, et al. The impact of surgical adjuvant thoracic radiation therapy for patients with nonsmall cell lung carcinoma with ipsilateral mediastinal lymph node involvement. Cancer. 1997;80(8):1399–1408. doi:10.1002/(SICI)1097-0142(19971015)80:8<1399::AID-CNCR6>3.0.CO;2-A9338463
   PubMed Web of Science ®Google Scholar
• Zhang B, Zhao L, Yuan Z, Pang Q, Wang P. The influence of the metastasis pattern of mediastinal lymph nodes on the postoperative radiotherapy’s efficacy for the IIIA-pN2 non-small-cell lung cancer: a retrospective analysis of 220 patients. Onco Targets Ther. 2016;9:6161–6169. doi:10.2147/OTT.S10356527785064
   PubMed Web of Science ®Google Scholar
• Mantovani A, Allavena P, Sica A, Balkwill F. Cancer-related inflammation. Nature. 2008;454(7203):436–444. doi:10.1038/nature0720518650914
   PubMed Web of Science ®Google Scholar
• Colotta F, Allavena P, Sica A, Garlanda C, Mantovani A. Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis. 2009;30(7):1073–1081. doi:10.1093/carcin/bgp12719468060
   PubMed Web of Science ®Google Scholar
• Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13(11):759–771. doi:10.1038/nrc361124154716
   PubMed Web of Science ®Google Scholar
• Takahashi Y, Kawamura M, Hato T, Harada M, Matsutani N, Horio H. Neutrophil-lymphocyte ratio as a prognostic marker for lung adenocarcinoma after complete resection. World J Surg. 2016;40(2):365–372. doi:10.1007/s00268-015-3275-226493696
   PubMed Web of Science ®Google Scholar
• Jiang G, Huang J, Cui T, Lin X, Lin G. A biomarker-based prediction model for risk of locoregional recurrence in pathologic stage IIIA-N2 non-small cell lung cancer. Int J Clin Exp Pathol. 2020;13(12):3060–3082.33425107
   PubMed Web of Science ®Google Scholar
• Wang YQ, Zhi QJ, Wang XY, Yue DS, Li K, Jiang RC. Prognostic value of combined platelet, fibrinogen, neutrophil to lymphocyte ratio and platelet to lymphocyte ratio in patients with lung adenosquamous cancer. Oncol Lett. 2017;14(4):4331–4338. doi:10.3892/ol.2017.666028943947
   PubMed Web of Science ®Google Scholar
• Sanchez-Salcedo P, De-torres JP, Martinez-Urbistondo D, et al. The neutrophil to lymphocyte and platelet to lymphocyte ratios as biomarkers for lung cancer development. Lung Cancer. 2016;97:28–34. doi:10.1016/j.lungcan.2016.04.01027237024
   PubMed Web of Science ®Google Scholar
• Yamauchi Y, Safi S, Muley T, et al. C-reactive protein-albumin ratio is an independent prognostic predictor of tumor recurrence in stage IIIA-N2 lung adenocarcinoma patients. Lung Cancer. 2017;114:62–67. doi:10.1016/j.lungcan.2017.11.00229173768
   PubMed Web of Science ®Google Scholar
• Jafri SH, Shi R, Mills G. Advance lung cancer inflammation index (ALI) at diagnosis is a prognostic marker in patients with metastatic non-small cell lung cancer (NSCLC): a retrospective review. BMC Cancer. 2013;13:158. doi:10.1186/1471-2407-13-15823530866
   PubMed Web of Science ®Google Scholar
• Guo W, Cai S, Zhang F, et al. Systemic immune-inflammation index (SII) is useful to predict survival outcomes in patients with surgically resected non-small cell lung cancer. Thorac Cancer. 2019;10(4):761–768. doi:10.1111/1759-7714.1299530734516
   PubMed Web of Science ®Google Scholar
• Shoji F, Morodomi Y, Akamine T, et al. Predictive impact for postoperative recurrence using the preoperative prognostic nutritional index in pathological stage I non-small cell lung cancer. Lung Cancer. 2016;98:15–21. doi:10.1016/j.lungcan.2016.05.01027393501
   PubMed Web of Science ®Google Scholar
• Uehara H, Nakao M, Mun M, et al. Significant prognostic factors for completely resected pN2 non-small cell lung cancer without neoadjuvant therapy. Ann Thorac Cardiovasc Surg. 2015;21(4):345–353. doi:10.5761/atcs.oa.14-0026225740454
   PubMed Web of Science ®Google Scholar
• Kobayashi S, Karube Y, Matsumura Y, et al. Inflammatory risk factors for early recurrence of non-small cell lung cancer within one year following curative resection. World J Surg. 2020;44(10):3510–3521. doi:10.1007/s00268-020-05612-032462215
   PubMed Web of Science ®Google Scholar
• US Department of Health and Human Services. The health consequences of smoking-50 years of progress: a report of the surgeon general. Atlanta (GA). 2014.
   Google Scholar
• Picciotto MR, Kenny PJ. Molecular mechanisms underlying behaviors related to nicotine addiction. Cold Spring Harb Perspect Med. 2013;3(1):a012112. doi:10.1101/cshperspect.a01211223143843
   PubMed Web of Science ®Google Scholar
• Dziedzic DA, Rudzinski P, Langfort R, Orlowski T; Polish Lung Cancer Study Group. Risk factors for local and distant recurrence after surgical treatment in patients with non-small-cell lung cancer. Clin Lung Cancer. 2016;17(5):e157–e167. doi:10.1016/j.cllc.2015.12.01326831834
   PubMed Web of Science ®Google Scholar
• Ohtaki Y, Shimizu K, Kaira K, et al. Risk factors associated with recurrence of surgically resected node-positive non-small cell lung cancer. Surg Today. 2016;46(10):1196–1208. doi:10.1007/s00595-015-1301-526782692
   PubMed Web of Science ®Google Scholar
• Borghetti P, Barbera F, Bonu ML, et al. Resected pN1 non-small cell lung cancer: recurrence patterns and nodal risk factors may suggest selection criteria for post-operative radiotherapy. Radiol Med. 2016;121(9):696–703. doi:10.1007/s11547-016-0648-z27230669
   PubMed Web of Science ®Google Scholar
• Matsuguma H, Oki I, Nakahara R, et al. Proposal of new nodal classifications for non-small-cell lung cancer based on the number and ratio of metastatic lymph nodes. Eur J Cardiothorac Surg. 2012;41(1):19–24. doi:10.1016/j.ejcts.2011.04.01621620720
   PubMed Web of Science ®Google Scholar
• Taylor MD, LaPar DJ, Thomas CJ, et al. Lymph node ratio predicts recurrence and survival after R0 resection for non-small cell lung cancer. Ann Thorac Surg. 2013;96(4):1163–1170. doi:10.1016/j.athoracsur.2013.04.03123998409
   PubMed Web of Science ®Google Scholar
• Isaka M, Kojima H, Takahashi S, Omae K, Ohde Y. Risk factors for local recurrence after lobectomy and lymph node dissection in patients with non-small cell lung cancer: implications for adjuvant therapy. Lung Cancer. 2018;115:28–33. doi:10.1016/j.lungcan.2017.11.01429290258
   PubMed Web of Science ®Google Scholar
• Aksoy Y, Citak N, Obuz C, Metin M, Sayar A. Does anatomical location-based metastatic lymph node density affect prognosis in lung cancer patients? Interact Cardiovasc Thorac Surg. 2021;33:541–549. doi:10.1093/icvts/ivab11934000035
   PubMed Web of Science ®Google Scholar
• Dziedzic DA, Cackowski MM, Zbytniewski M, et al. The influence of the number of lymph nodes removed on the accuracy of a newly proposed N descriptor classification in patients with surgically-treated lung cancer. Surg Oncol. 2021;37:101514. doi:10.1016/j.suronc.2020.12.00833429325
   PubMed Web of Science ®Google Scholar
• Candido J, Hagemann T. Cancer-related inflammation. J Clin Immunol. 2013;33(Suppl 1):S79–84. doi:10.1007/s10875-012-9847-023225204
   PubMed Web of Science ®Google Scholar
• Lei T, Li J, Zhong H, et al. Postoperative radiotherapy for patients with resectable stage III-N2 non-small cell lung cancer: a systematic review and meta-analysis. Front Oncol. 2021;11:680615. doi:10.3389/fonc.2021.68061534336667
   PubMed Web of Science ®Google Scholar
• Hui Z, Men Y, Hu C, et al. Effect of postoperative radiotherapy for patients with pIIIA-N2 non-small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT-C randomized clinical trial. JAMA Oncol. 2021;7(8):1178–1185. doi:10.1001/jamaoncol.2021.191034165501
   PubMed Web of Science ®Google Scholar
• Xu L, Xie HN, Chen XK, Bi N, Qin JJ, Li Y. Patient prognostic scores and association with survival improvement offered by postoperative radiotherapy for resected IIIA/N2 non-small cell lung cancer: a population-based study. Thorac Cancer. 2021;12(6):760–767. doi:10.1111/1759-7714.1383533481353
   PubMed Web of Science ®Google Scholar
• Tian C, Liu G, Xu Y, et al. Postoperative radiotherapy for patients with completely resected pathological stage IIIA-N2 non-small cell lung cancer: a preferential benefit for squamous cell carcinoma. Radiol Oncol. 2020;55(1):66–76. doi:10.2478/raon-2020-007033885242
   PubMed Web of Science ®Google Scholar